Skip to main content

Table 4 Correlation of UGT1A polymorphisms with severe toxicity

From: Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis

 

Severe diarrhea

Severe neutropenia

Severe toxicity

Genotype

N/Total(%)

P value

N/Total(%)

P value

No.(%)

P value

UGT1A1*6/*28 panels (N = 661)

 Wild typea

31/368(8.4%)

 

59/368(16.0%)

 

84/368(22.8%)

 

 Single allele variantsb

23/228(10.1%)

 

53/228(23.2%)

 

66/228(28.9%)

 

 ≧2 alleles variantsc

5/65(7.7%)

0.736

24/65(36.9%)

<0.001

29/65(44.6%)

0.001

UGT1A1*6/*28 and DPYD*5 panels (N = 496)

 Wild typed

5/114(4.4%)

 

17/114(14.9%)

 

20/114(17.5%)

 

 Single allele variantse

22/214(10.3%)

 

36/214(16.8%)

 

54/214(25.2%)

 

 2 alleles variantsf

12/124(9.7%)

 

37/124(29.8%)

 

44/124(35.5%)

 

 ≧3 alleles variantsg

7/44(15.9%)

0.147

14/44(31.8%)

0.008

21/44(47.7%)

0.001

  1. apatients with genotype: G/G and TA6/TA6. bpatients with genotype: G/A, and TA6/TA6; or G/G and TA6/TA7. cpatients with genotype: A/A and TA6/TA6; or G/A and TA6/TA7; or G/G and TA7/TA7; or A/A and TA6/TA7. dpatients with genotype: G/G, TA6/TA7 and A/A. epatients with genotype: G/A, TA6/TA6 and A/A; or G/G, TA6/TA7 and A/A; or G/G, TA6/TA6, A/G. fpatients with genotype: G/A, TA6/TA7 and A/A; or G/G, TA6/TA6 and G/G; or G/G, TA7/TA7 and A/A; A/A, TA6/TA6 and A/A. gpatients with genotype: G/A, TA6/TA7 and A/G; or A/A, TA6/TA6 and A/G; or G/G, TA7/TA7 and G/G; or G/A, TA6/TA7 and G/G; or A/A, TA6/TA6 and G/G
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us